PharmaGossip reports via the WSJ that Sanofi has finished its due diligence with Genzyme with no major issues uncovered, but still hasn't agreed to final price yet. The question remains whether Sanofi will agree to a CVR and if so at what price - previous reports have pegged the initial CVR value at $2 per share with it having the possibility to reach $5-6 per share.
This report says Sanofi may not agree to any CVR and merely wish to stick to an offer or about $74 per share or about $19 B. Ok. OK Already. Let's get this deal done. It's like lingering death and each of these reports add little if anything new to the story.
Wake me when it is over.
Posted by Bruce Lehr Feb 14th 2011.